Cystic fibrosis is a life-threatening disease that causes mucus to build up and clog some of the organs in the body, particularly in the lungs and pancreas. When mucus clogs the lungs, it can make breathing very difficult. The thick mucus also causes bacteria (or germs) to get stuck in the airways, which causes inflammation (or swelling) and infections that leads to lung damage. Mucus also can block the digestive tract and pancreas.

Cystic fibrosis is a genetic disease. That means people inherit it from their parents through genes (or DNA), which also determine a lot of other characteristics including height, hair color and eye color. Genes, found in the nucleus of all the body's cells, control cell function by serving as the blueprint for the production of proteins. The defective gene that is responsible for causing cystic fibrosis is on chromosome 7.

Approximately 30,000 people in the United States have cystic fibrosis. An additional ten million more—or about one in every 31 Americans—are carriers of the defective CF gene, but do not have the disease. The disease is most common in Caucasians, but it can affect all races. The severity of cystic fibrosis symptoms is different from person to person.

Currently, there is no cure for cystic fibrosis. However, specialized medical care, aggressive drug treatments, and therapies, along with proper CF nutrition, can lengthen and improve the quality of life for those with CF. The best way for people with cystic fibrosis to fight their disease is to work with their medical caregivers at a CF Foundation-accredited care center. The care center partners with people who have CF to help keep them in the best health possible.

The 79th Texas Legislature in 2005 mandated that DSHS expand to the ACMG-recommended panel of disorders as funding allowed and appropriated $3.1 million. The startup funding allows 20 additional disorders to be added to the screening panel. Cystic fibrosis startup would require an additional $2 million to $3 million.

CF is one of the most common inherited diseases of Caucasians (whites). CF occurs in one of every 3,200 live Caucasian births. It occurs in one in every 15,000 live African-American births. CF is uncommon in Asians and most Native American tribes. It is being seen more often in Hispanics. CF affects almost every race. About 1,000 new cases of CF are diagnosed each year.

No. CF is a disease that a person is born with. It comes from a defective gene from each parent. Genes are the main unit of heredity. Not all people carry the defective gene that causes CF, so if one parent has the gene and the other does not, the child will not have CF. You cannot control which genes get passed to your child.

People with CF can have several symptoms including very salty-tasting skin; steady coughing at times with phlegm; wheezing or shortness of breath; a huge appetite but remains thin; and large, greasy stools. These symptoms are different from person to person.

The main test for CF is called the sweat test and it measures the amount of salt in sweat. Starting in 2002, all babies born in New York State are tested at birth as part of a series of tests on newborn babies. If there is reason to think a child has CF, the test should be done in an accredited CF Care Center.

There are many treatments for the symptoms and CF related problems. Treatment is aimed at preventing lung infections, reducing the amount and thickness of mucous in the lungs, improving airflow and maintaining nutrition.

There is no cure for CF at this time, but ongoing research has led to advances in treatment, which have significantly improved the lives of many CF patients. New discoveries in the treatment of CF have helped people with the disease live longer. Twenty years ago, only half the people with CF lived beyond age 21, but today half the people with CF live past 35 years of age.

Open Directory - Science: Biology: Genetics: Eukaryotic: Animal: Mammal: Human: Testing and Counseling EBI, the European Bioinformatics Institute (EMBL Outstation, Hinxton, UK) serving the bioinformatics community

In November 2006, we presented data from the PTC124 cystic fibrosis clinical trials in Israel and the U.S. Cystic fibrosis is caused by a lack of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. To determine whether PTC124 was inducing production of active CFTR protein in patients, we measured nasal transepithelial potential difference (TEPD).

Visit the Cystic Fibrosis Foundation website for information and links to further resources on this disease. For more detailed information, including discoverer Riordan et al., please read the following articles at NCBI. PathoGenesis Corporation, who played a major role in sequencing the first P. aeruginosa genome, is now a part of Chiron and continues its interest in the development of new anti-Pseudomonad drugs.

Dental X-rays- Dental caries- Dental injuries -Dental plaque identification procedure and removal Denture problems American Diabetes Assoc. - self assessment test that will help determine whether yu are at high risk, how to reduce your risk through exercise and diet.

How does Assista compare to Yahoo Answers? First, these are totally different systems. “Yahoo Answers” is more of a Q&A type site where they only list questions from their own database while Assista aggregates content (questions) from every web page on the internet, including all of “Yahoo Answers” questions.

He also presents very questionable information, revealing his real intent, in spite of any disclaimers he might use: What precautions should be taken while detoxifying and deep cleansing? The person may have a condition of diabetes, multiple sclerosis or lung conditions. People with health problems should work with a qualified practitioner while cleansing. Diabetes, multiple sclerosis and lung conditions are serious conditions.

Phase 2a studies are typically conducted on a relatively small number of patients, with the goal of determining drug activity, evaluating short-term side effects, and assessing pharmacokinetics in patients. The duration of several of the initial Phase 2a studies has been based on knowledge that PTC124 is safe when given for up to 28 days to animals and because it has been expected that early drug effects in patients might be observed within this duration of treatment.